AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
CARISMA Therapeutics Plunges 27.93% Amid Volatility
Generated by AI AgentAinvest Pre-Market Radar
Wednesday, Jun 11, 2025 4:15 am ET1min read
On June 11, 2025,
experienced a significant drop of 27.93% in pre-market trading, marking a notable shift in investor sentiment towards the company.In recent trading sessions, CARISMA Therapeutics has shown considerable volatility. The company's shares have seen substantial gains in previous sessions, with reports indicating a rise of 84.56% to $0.42 during Tuesday's pre-market session. This upward trend followed a 71.69% increase to $0.39 during the previous pre-market session, building on a 16.97% gain from the day before. The stock's performance has been characterized by significant activity, with a notable 233.0% increase in trading volume on the same day.
The company's recent performance has been driven by a series of positive developments. On the last trading day, the stock price gained 389.42%, rising from $0.227 to $1.11. This surge in stock price reflects growing investor confidence in the company's prospects. The upward trend in CARISMA Therapeutics' stock price is indicative of a broader market interest in the healthcare sector, with the company's innovative therapies and treatments attracting attention from investors.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Metallus shares plunge 6.73% as investor concerns over earnings volatility and sector risks grow
Dec.22 2025
Annexon (ANNX) Surges 7.26% in Pre-Market Trading After S&P Biotechnology Index Inclusion
Dec.22 2025
Aeva Technologies Inc. surges 7.69% on strategic partnership with major automaker
Dec.22 2025
Oracle shares surge 6.63% on OpenAI rebuttal and healthcare contracts
Dec.22 2025
Broadcom Inc. (NASDAQ:AVGO) surges 3.18% on analyst upgrades amid AI growth optimism
Dec.22 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet